1. Empagliflozin in heart failure with preserved ejection fraction: decoding its molecular mechanism of action using artificial intelligence. (14th October 2021) Authors: Iborra Egea, O; Spitaleri, G; Domingo, M; Revuelta Lopez, E; Codina, P; Cediel, G; Santiago Vacas, E; Cserkoova, A; Pascual Figal, D; Nunez, J; Lupon, J; Bayes Genis, A Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Issue 1 (January 2022) Authors: Verma, Subodh; Dhingra, Nitish K; Butler, Javed; Anker, Stefan D; Ferreira, Joao Pedro; Filippatos, Gerasimos; Januzzi, James L; Lam, Carolyn S P; Sattar, Naveed; Peil, Barbara; Nordaby, Matias; Brueckmann, Martina; Pocock, Stuart J; Zannad, Faiez; Packer, Milton; Packer, M; Anker, S; Butler, J; ... Journal: Lancet Issue: Volume 10:Issue 1(2022) Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P6539Patient-associated predictors of 15- and 30-day readmission after hospitalization for Acute Heart Failure. (28th August 2018) Authors: Rodriguez Chaverri, A; Ponz De Antonio, I; Moran Fernandez, L; Bascompte Claret, R; Grau Sepulveda, A; Fernandez-Aviles, F; Gonzalez-Juanatey, J R; Vazquez Garcia, R; Rivera Otero, M; Segovia Cubero, J; Pascual Figal, D; Crespo-Leiro, M; Cinca Cuscullola, J; Arribas Ynsaurraga, F; Delgado Jimenez... Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗